| Literature DB >> 25006447 |
Julia L Goldman1, Saad Sammani2, Carrie Kempf3, Laleh Saadat2, Eleftheria Letsiou2, Ting Wang3, Liliana Moreno-Vinasco2, Alicia N Rizzo2, Jeffrey D Fortman4, Joe G N Garcia5.
Abstract
Patients with acute respiratory distress syndrome (ARDS) exhibit elevated levels of interleukin-6 (IL-6), which correlate with increased morbidity and mortality. The exact role of IL-6 in ARDS has proven difficult to study because it exhibits either pro- or anti-inflammatory actions in mouse models of lung injury, depending on the model utilized. In order to improve understanding of the role of this complex cytokine in ARDS, we evaluated IL-6 using the clinically relevant combination of lipopolysaccharide (LPS) and ventilator-induced lung injury (VILI) in IL-6(-/-) mice. Bronchoalveolar lavage fluid (BAL), whole-lung tissue, and histology were evaluated for inflammatory markers of injury. Transendothelial electrical resistance was used to evaluate the action of IL-6 on endothelial cells in vitro. In wild-type mice, the combination model showed a significant increase in lung injury compared to either LPS or VILI alone. IL-6(-/-) mice exhibited a statistically significant decrease in BAL cellular inflammation as well as lower histologic scores for lung injury, changes observed only in the combination model. A paradoxical increase in BAL total protein was observed in IL-6(-/-) mice exposed to LPS, suggesting that IL-6 provides protection from vascular leakage. However, in vitro data showed that IL-6, when combined with its soluble receptor, actually caused a significant increase in endothelial cell permeability, suggesting that the protection seen in vivo was likely due to complex interactions of IL-6 and other inflammatory mediators rather than to direct effects of IL-6. These studies suggest that a dual-injury model exhibits utility in evaluating the pleiotropic effects of IL-6 in ARDS on inflammatory cells and lung endothelium.Entities:
Keywords: acute respiratory distress syndrome (ARDS); interleukin-6 (IL-6); lipopolysaccharide (LPS); ventilator-induced lung injury (VILI)
Year: 2014 PMID: 25006447 PMCID: PMC4070787 DOI: 10.1086/675991
Source DB: PubMed Journal: Pulm Circ ISSN: 2045-8932 Impact factor: 3.017